CL2021000269A1 - Métodos para tratar trastornos neurodegenerativos - Google Patents
Métodos para tratar trastornos neurodegenerativosInfo
- Publication number
- CL2021000269A1 CL2021000269A1 CL2021000269A CL2021000269A CL2021000269A1 CL 2021000269 A1 CL2021000269 A1 CL 2021000269A1 CL 2021000269 A CL2021000269 A CL 2021000269A CL 2021000269 A CL2021000269 A CL 2021000269A CL 2021000269 A1 CL2021000269 A1 CL 2021000269A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- neurodegenerative disorders
- treat neurodegenerative
- treat
- disorders
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960003570 tramiprosate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713061P | 2018-08-01 | 2018-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021000269A1 true CL2021000269A1 (es) | 2021-06-18 |
Family
ID=67614642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021000269A CL2021000269A1 (es) | 2018-08-01 | 2021-02-01 | Métodos para tratar trastornos neurodegenerativos |
Country Status (27)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021001287A (es) * | 2018-08-01 | 2021-07-15 | Alzheon Inc | Métodos para tratar trastornos neurodegenerativos. |
| PH12021553196A1 (en) * | 2019-06-17 | 2022-11-07 | Alzheon Inc | Methods for treating neurodegenerative disorders |
| AU2022405026A1 (en) * | 2021-12-09 | 2024-06-20 | Alzheon, Inc. | Alz-801 for use in treating alzheimer's disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| SI2089417T1 (sl) * | 2006-10-12 | 2015-04-30 | Bhi Limited Partnership | Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline |
| EP2852388A4 (en) | 2012-05-23 | 2016-01-13 | Univ Johns Hopkins | COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| WO2014121083A1 (en) * | 2013-01-31 | 2014-08-07 | President And Fellows Of Harvard College | Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition |
| ES2960625T3 (es) * | 2014-03-21 | 2024-03-05 | Alzheon Inc | Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+ |
| EP3347002B1 (en) * | 2015-09-10 | 2023-06-07 | Alzheon, Inc. | Treatment of alzheimer's disease in a particular patient population |
| MX2021001287A (es) * | 2018-08-01 | 2021-07-15 | Alzheon Inc | Métodos para tratar trastornos neurodegenerativos. |
-
2019
- 2019-07-30 MX MX2021001287A patent/MX2021001287A/es unknown
- 2019-07-30 BR BR112021001739-9A patent/BR112021001739A2/pt unknown
- 2019-07-30 US US17/264,477 patent/US12083082B2/en active Active
- 2019-07-30 EA EA202190406A patent/EA202190406A1/ru unknown
- 2019-07-30 AU AU2019315853A patent/AU2019315853B2/en active Active
- 2019-07-30 SI SI201930898T patent/SI3829563T1/sl unknown
- 2019-07-30 PL PL19752795.5T patent/PL3829563T3/pl unknown
- 2019-07-30 ES ES19752795T patent/ES3011716T3/es active Active
- 2019-07-30 MY MYPI2021000515A patent/MY206530A/en unknown
- 2019-07-30 SG SG11202100767XA patent/SG11202100767XA/en unknown
- 2019-07-30 IL IL280424A patent/IL280424B2/en unknown
- 2019-07-30 HR HRP20250206TT patent/HRP20250206T1/hr unknown
- 2019-07-30 HU HUE19752795A patent/HUE070101T2/hu unknown
- 2019-07-30 DK DK19752795.5T patent/DK3829563T3/da active
- 2019-07-30 LT LTEPPCT/US2019/044023T patent/LT3829563T/lt unknown
- 2019-07-30 KR KR1020217005803A patent/KR102716959B1/ko active Active
- 2019-07-30 EP EP19752795.5A patent/EP3829563B1/en active Active
- 2019-07-30 RS RS20250164A patent/RS66516B1/sr unknown
- 2019-07-30 WO PCT/US2019/044023 patent/WO2020028290A1/en not_active Ceased
- 2019-07-30 CN CN201980064415.6A patent/CN112867485A/zh active Pending
- 2019-07-30 FI FIEP19752795.5T patent/FI3829563T3/fi active
- 2019-07-30 JP JP2021505721A patent/JP7573512B2/ja active Active
- 2019-07-30 PT PT197527955T patent/PT3829563T/pt unknown
- 2019-07-30 UA UAA202101015A patent/UA130011C2/uk unknown
- 2019-07-30 SM SM20250080T patent/SMT202500080T1/it unknown
-
2021
- 2021-01-28 PH PH12021550213A patent/PH12021550213A1/en unknown
- 2021-02-01 CL CL2021000269A patent/CL2021000269A1/es unknown
-
2024
- 2024-08-02 US US18/793,452 patent/US20250213507A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001709A1 (es) | Derivados pirazol como inhibidores de malt1. | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| MX389513B (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| MX2020009602A (es) | Formulaciones de pulverizacion de epinefrina. | |
| SV2017005434A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| BR112018000691A2 (pt) | inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
| MX375424B (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl | |
| CR20160352A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| MX375372B (es) | COMPOSICIONES DE COMPUESTOS DE MOLÉCULA PEQUEÑA Y USO DE LOS MISMOS COMO INHIBIDORES TrKA. | |
| MX2018012902A (es) | Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal. | |
| CR20200214A (es) | ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y | |
| CU20160151A7 (es) | 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
| EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
| MX2019000980A (es) | Compuestos y composiciones y usos de los mismos. | |
| ECSP17035415A (es) | 2-Amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1 | |
| MX2023012640A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
| MX2018012230A (es) | Métodos para tratar enfermedades oculares. | |
| MX377304B (es) | Derivados de piperazina como moduladores de los receptores x del hígado. | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| CY1124821T1 (el) | Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ | |
| MX2021001287A (es) | Métodos para tratar trastornos neurodegenerativos. | |
| MA47595A (fr) | Méthodes de traitement d'affections neurodégénératives | |
| MX2016012645A (es) | Composiciones y metodos para tratar enfermedades neurodegenerativas. |